Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
Guillermo Garcia‐Manero, Ghulam J. Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, María Díez‐Campelo, Carlo Finelli, Osman İlhan, Mikkael A. Sekeres, Amer M. Zeidan, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Jay T. Backstrom, Uwe Platzbecker, Rami S. Komrokji
Abstract
Luspatercept may induce RBC transfusion independence but also Neutrophil and platelet increases in lower-risk MDS: secondary endpoints from the MEDALIST trial
Topics & Concepts
MedicineInternal medicineClinical endpointRomiplostimPlateletClinical trialThrombopoietinBiologyGeneticsStem cellHaematopoiesisAcute Myeloid Leukemia ResearchInflammatory Biomarkers in Disease PrognosisMyeloproliferative Neoplasms: Diagnosis and Treatment